Korean journal of aerospace and environmental medicine (항공우주의학회지)

Aerospace Medical Association of Korea (한국항공우주의학협회)
권호 표지
DOI QR코드

DOI QR Code

Human Papillomavirus Vaccination for Foreigners during COVID-19 Era

COVID-19 시대에서 외국인의 자궁경부암 백신접종

  • Lim, Juwon (International Healthcare Center, Seoul National University Hospital)
  • 임주원 (서울대학교병원 국제진료센터)
  • Received : 2021.04.08
  • Accepted : 2021.04.11
  • Published : 2021.04.30
⟨ Previous Next ⟩

Abstract

Purpose: Human papillomavirus (HPV) vaccination schedule is recommended by Strategic Advisory Group of Experts on Immunization of World Health Organization to achieve high efficacy and immunogenicity. However, the patients often cannot keep up their schedule for several reasons. Methods: Monthly numbers of visitors for HPV vaccination between 2019 and 2021 were analyzed to measure the impact of coronavirus disease-19 (COVID-19) outbreak which was the main cause of this delay. Results: In February 2020, the number of foreign patients vaccinated with HPV was dropped suddenly due to COVID-19. Prior to this impact, the average patients per month for HPV vaccination was 160 (95% confidence interval [CI]: 143-176). It was then 30 (95% CI: 20-40). However recent trends show a gradual recovery. Conclusion: If a woman is pregnant after starting the HPV vaccine series, the reminder doses should be delayed until she is no longer pregnant. If this series is interrupted for any length of time, it can be resumed without restarting the series. HPV vaccine series need to be administered with a minimum interval of 14 days before or after administration of COVID-19 vaccines.

Keywords

References

  1. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-789. https://doi.org/10.1001/jama.290.6.781
  2. Freedman M, Kroger A, Hunter P, Ault KA; Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2020. Ann Intern Med 2020;172:337-347. https://doi.org/10.7326/M20-0046
  3. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al.; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014;63(RR-05):1-30.
  4. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al.; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372:711-723. https://doi.org/10.1056/NEJMoa1405044
  5. GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-1985. https://doi.org/10.1016/S0140-6736(09)61567-1
  6. Oshman LD, Davis AM. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). JAMA 2020;323:468-469. https://doi.org/10.1001/jama.2019.18411
  7. Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, et al.; Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015;64:300-304.
  8. Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States [Internet]. Atlanta (GA): National Center for Immunization and Respiratory Diseases; 2021 [updated 2021 Mar 5; cited 2021 Apr 5]. Available from: https://www.cdc.gov/vaccines/covid-19/info-byproduct/clinical-considerations.html.
  9. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21:181-192. https://doi.org/10.1016/S1473-3099(20)30843-4